Table 1.
Outcomes at prostatectomy for intent-to-treat population
| AAP+LHRHa | LHRHa | p valuea | |
|---|---|---|---|
| N | 44 | 21 | |
| Surgery | |||
| Robotic-assisted prostatectomy | 40 | 18 | |
| Lymph nodes, median (Q1, Q3) | 19.5 (12–25) | 19 (16–22) | |
| Perioperative serious AE | 1 PE | 1 pelvic bleeding | |
| Blood loss (ml), median (Q1, Q3) | 250 (187–300) | 250 (150–300) | |
| Pathology | |||
| ypT2N0, n (%) | 21 (48) | 7 (33) | 0.27 |
| Surgical margin negative, n (%) | 42 (95) | 18 (86) | 0.17 |
| Lymph nodes negative, n (%) | 29(66) | 13 (62) | 0.75 |
| PSA nadirb, n | 44 | 21 | |
| PSA ≤0.1 ng/ml | 37 (84) | 1 (5) | <0.0001 |
AAP = abiraterone acetate plus prednisone; AE = adverse event; LHRHa = luteinising hormone-releasing hormone agoinst; PE = pulmonary embolism; PSA = prostate-specific antigen: Q1 and Q3 =25th and 75th percentiles, respectively.
a
Based on chi-square test.
b
Lowest PSA level during study (excluding postprostatectomy visit).